On 2 May 2026 Malaysia's regulator (NPRA) opened a one-year pilot - a new "recognition" route within its Facilitated Registration Pathway (FRP). A drug already approved by the US FDA or the EMA (centralised procedure; decentralised for generics only) can be registered in Malaysia on an accelerated basis, with an administrative target of 60 working days. The trade-off is strict sameness: the dossier, formulation, manufacturing sites and risk management plan must be identical to what the reference agency approved, with no post-approval changes - and you must file within 3 months of that approval. A locally incorporated Marketing Authorisation Holder (MAH) submits via the QUEST system.
For years the honest answer to "how long does registration take in Malaysia?" was "plan for the better part of a year, sometimes longer." For manufacturers whose product is already approved by a top-tier regulator, that felt like paying twice. The FRP recognition pilot is NPRA's answer - and because it only opened in May 2026, very little practical guidance exists yet. This is what it actually says.
What the FRP recognition pilot is
The Facilitated Registration Pathway is NPRA's framework for regulatory reliance - leveraging a trusted authority's prior approval instead of repeating a full assessment. It already had two routes (Abbreviated and Verification review). On 2 May 2026 NPRA added a new recognition route as a one-year pilot, expanding the pathway "in addition to the existing verification and abbreviated routes." The pilot is explicitly a test "before extending the pathway to products approved by other reference agencies" - so today it is limited to two.
Who qualifies: agencies, products, the "sameness" rule
Reference agencies (pilot). Only two, for now:
- US FDA - new drug products, biologics and generics.
- EMA, centralised procedure - new drug products, biologics and generics.
- EMA, decentralised procedure - generics only.
The core condition is "sameness." Under NPRA's Declaration of Sameness, the product submitted to Malaysia must be identical to the one the reference agency approved, including:
- active ingredient(s), strength(s), dosage form and route of administration;
- indication(s) and posology, formulation composition, and container closure system;
- identical manufacturing, packaging, testing and batch-release sites (a secondary repacker is allowed only if justified and backed by a GMP certificate NPRA recognizes);
- an identical dossier - "no data added, modified, substituted or omitted" and no post-approval changes;
- an identical Risk Management Plan.
Excluded. Conditional approvals and other "exceptional circumstances" authorisations do not qualify, and products that would need a more stringent local assessment (for example some anti-infectives, due to local disease patterns) are out of scope.
Timeline and the 3-month window
NPRA states an administrative target of 60 working days, counted from confirmation of payment after the application passes screening (time spent waiting for the applicant to respond does not count). Correspondence is capped at three rounds; missing them can drop the application back to the standard full-evaluation timeline.
The window is the part teams underestimate: the reference-agency approval must be recent - under NPRA's Declaration of Sameness it must generally have been granted no more than 3 months before submission to NPRA. (NPRA's announcement and the Declaration word the start of this clock slightly differently, so confirm the exact mechanics before you plan around a specific date.) In practice, treat the EMA or FDA approval date as the moment the clock to file in Malaysia starts.
The pilot is new. The exact mechanics of the 3-month clock, fee amounts, GMP-evidence specifics and stability-data minimums should be confirmed against NPRA's final FRP guidance before you build a submission plan around them. NPRA also retains full discretion to request more documents or decline an application.
FRP vs the other NPRA routes
The recognition pilot sits alongside the existing reliance routes. Indicative, NPRA-stated administrative timelines (excluding screening and applicant response time):
| Route | Basis | Indicative timeline |
|---|---|---|
| Full evaluation | New chemical entities, no reliance | the longest route |
| Verification review | Approved by two reference agencies / ASEAN joint assessment | 30 working days |
| Abbreviated review | Approved by one reference agency | 90 working days |
| Recognition pilot (FRP, 2026) | US FDA or EMA approval + strict sameness | 60 working days |
The recognition route's advantage is not only speed but a lower qualification bar: a single EMA or FDA approval is enough, where verification review needs two.
What to prepare
- Proof of the reference-agency approval and the unredacted assessment report.
- The identical dossier as approved, plus the signed Declaration of Sameness.
- Malaysian-compliant labelling and the Risk Management Plan (identical to the approved one).
- Stability data to ASEAN Climate Zone IVb (confirm the current minimum against NPRA guidance).
- A locally incorporated MAH - a Malaysian legal entity - to submit via QUEST and manage the (max three) correspondence rounds. (Who that entity is matters: see our companion guide on keeping control of your registration.)
Why this matters for EU manufacturers
For an EU manufacturer, the recognition pilot is the cleanest fast entry to date: an EMA centralised approval qualifies on its own (new drugs, biologics and generics; decentralised approvals cover generics), with no need for a second reference approval. Because the route requires manufacturing sites identical to those EMA approved, and Malaysia and EU regulators both participate in the PIC/S GMP framework, EU-GMP evidence generally fits NPRA's expectations (confirm the exact GMP documentation NPRA wants for your foreign sites). File within three months of EMA approval, submit the same dossier with the assessment report and Declaration of Sameness, and you are targeting a roughly 60-working-day review instead of a full one.
If your drug is already approved by the US FDA or EMA, Malaysia's FRP recognition pilot can register it on a ~60-working-day target - provided the submission is identical to the approved product and filed within 3 months of that approval.
Frequently asked questions
What is Malaysia's FRP recognition pilot?
A one-year pilot from 2 May 2026 that adds a new "recognition" route to NPRA's Facilitated Registration Pathway. It gives drugs already approved by the US FDA or EMA an accelerated review with a target of 60 working days.
Which approvals qualify?
A US FDA approval, or an EMA approval through the centralised procedure (new drugs, biologics and generics); the EMA decentralised procedure qualifies for generics only. Other agencies are expected to be added after the pilot.
Does an EMA approval alone qualify?
Yes - an EMA centralised approval is sufficient on its own for new drugs, biologics and generics; you do not need a second reference approval. (EMA decentralised approvals qualify for generics only.)
How fast is it?
NPRA's administrative target is 60 working days, counted from confirmation of payment after screening, excluding time spent waiting for the applicant to respond. Correspondence is limited to three rounds.
What is the catch?
Strict "sameness": the dossier, formulation, manufacturing sites and Risk Management Plan must be identical to the reference-agency approval with no post-approval changes, and you must file within three months of that approval. Conditional approvals are excluded.
Who submits the application?
A locally incorporated Marketing Authorisation Holder (MAH) submits via the QUEST system on the manufacturer's behalf.
- Sources (primary, NPRA):
- NPRA - "New Route under the Facilitated Registration Pathway (FRP): a one-year pilot study commencing 2 May 2026": npra.gov.my (announcement)
- NPRA - Declaration of Sameness and Compliance for the New Route (Appendix 1): npra.gov.my (Appendix 1, PDF)
- NPRA - Guideline on Facilitated Registration Pathway (Nov 2023), Abbreviated & Verification routes: npra.gov.my (FRP guideline)
- Editorial note: This article is general business and regulatory information for manufacturers evaluating Malaysia. It is not legal or regulatory advice. The FRP recognition route is a new pilot - confirm current eligibility, timelines, fees and documentation against NPRA's official guidance before acting.